Duexis

Zollinger-Ellison Syndrome, Curling Ulcer, Indigestion + 21 more

Treatment

4 FDA approvals

20 Active Studies for Duexis

What is Duexis

Famotidine

The Generic name of this drug

Treatment Summary

Famotidine is a medication used to reduce the production of stomach acid. It works by blocking the histamine-2 receptor, which helps to inhibit acid secretion in the stomach. It is commonly used to treat conditions such as gastric ulcers and GERD in both adults and children. It is more potent than similar medications, such as cimetidine and ranitidine, and can be taken as a pill or intravenously in a hospital setting.

Pepcid

is the brand name

image of different drug pills on a surface

Duexis Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Pepcid

Famotidine

1986

623

Approved as Treatment by the FDA

Famotidine, also called Pepcid, is approved by the FDA for 4 uses which include Heartburn and Heartburn .

Heartburn

Heartburn

prophylaxis of Heartburn

Heartburn

Effectiveness

How Duexis Affects Patients

Famotidine works by reducing acid in the stomach and decreasing the amount of acid and digestive enzymes produced. It's effects can be felt within one hour and last up to 12 hours. The more you take, the longer it will last and the more it will reduce your stomach acid.

How Duexis works in the body

Histamine is a hormone that tells stomach cells to produce acid. This happens when enterochromaffin-like cells release histamine, which is also triggered by the hormone gastrin. Histamine binds to receptors on the stomach cells, which increases the production of acid. In cases of ulcers or other conditions where too much acid is produced, famotidine steps in. Famotidine blocks the action of histamine on the stomach cells, reducing the amount of acid they produce.

When to interrupt dosage

The proposed measure of Duexis is contingent upon the diagnosed circumstance, such as Heartburn, Heartburn and Pathological Conditions, Anatomical. The measure of dosage is contingent upon the mode of administration (e.g. Tablet, film coated - Oral or Oral) exemplified in the table beneath.

Condition

Dosage

Administration

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Collagen Diseases

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Erosive Esophagitis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Obesity

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Zollinger-Ellison Syndrome

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Gastric ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Multiple Endocrine Neoplasia

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Critical Illness

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Spasm

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pathological Conditions, Anatomical

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Helicobacter Pylori Infection

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Osteoarthritis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Chronic Back Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

prophylaxis of Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Duodenal Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stomach Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Warnings

Duexis has one contraindication, so it ought not to be taken in combination with the conditions indicated in the following table.

Duexis Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Duexis.

Common Duexis Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Famotidine.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Famotidine.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Famotidine.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Famotidine.

Atazanavir

Major

Famotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.

Duexis Toxicity & Overdose Risk

The lowest dose of famotidine that has been found to be toxic in rats is 4049mg/kg, and 4686mg/kg in mice. The lowest toxic dose in humans is 4mg/kg, taken over a 7 day period. Symptoms of famotidine overdose are similar to those of recommended doses, and can be treated with supportive and symptomatic care. Removing unabsorbed drug from the gastrointestinal system and monitoring the patient is necessary. Hemodialysis can also be used to remove the drug from the bloodstream.

image of a doctor in a lab doing drug, clinical research

Duexis Novel Uses: Which Conditions Have a Clinical Trial Featuring Duexis?

45 active clinical trials are examining the potential of Duexis to ameliorate Collagen Diseases, Acid Indigestion and Muscle Spasms.

Condition

Clinical Trials

Trial Phases

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Chronic Back Pain

5 Actively Recruiting

Not Applicable

Collagen Diseases

0 Actively Recruiting

Gastric ulcer

0 Actively Recruiting

Critical Illness

0 Actively Recruiting

Gastritis

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Zollinger-Ellison Syndrome

0 Actively Recruiting

Curling Ulcer

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Multiple Endocrine Neoplasia

0 Actively Recruiting

Stress Ulcers

0 Actively Recruiting

Heartburn

0 Actively Recruiting

Spasm

0 Actively Recruiting

Erosive Esophagitis

2 Actively Recruiting

Phase 2, Phase 3

Obesity

0 Actively Recruiting

Pathological Conditions, Anatomical

3 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Osteoarthritis

0 Actively Recruiting

prophylaxis of Stress Ulcers

0 Actively Recruiting

Duexis Reviews: What are patients saying about Duexis?

5

Patient Review

8/6/2016

Duexis for Osteoarthritis and High Risk of Developing Gastric Ulcers

This treatment is really effective. I take it along with norco 10 and it does a great job at relieving my pain.

5

Patient Review

2/1/2019

Duexis for Joint Damage causing Pain and Loss of Function

The manufacturer's discount on this drug was incredible--60 pills for only $10. However, they withdrew the discount and now each pill costs $2,000. I've had to switch to taking ibuprofen and Pepcid ac daily, which is a real bummer. If you're on Medicare, beware that you won't be able to receive the discount either.

5

Patient Review

11/6/2016

Duexis for Osteoarthritis and High Risk of Developing Gastric Ulcers

I started taking this medication because I was having stomach problems with other pills. However, this pill helped my lower back pain.

5

Patient Review

12/22/2016

Duexis for Joint Damage causing Pain and Loss of Function

This drug has been a huge help for my plantar fasciitis.

5

Patient Review

3/27/2016

Duexis for Joint Damage causing Pain and Loss of Function

5

Patient Review

5/19/2017

Duexis for Rheumatoid Arthritis

Out of all the pills I've taken for my osteoarthritis, Duexis is the only one that's actually helped me. Not to mention, their co-pay card has been a lifesaver.

3.7

Patient Review

3/20/2019

Duexis for Gout

Kicks in 15-30 min and allows me to take it as needed. It manages any pain flare ups after a busy weekend doing yard work or house work. It works great and does not affect my GERD. My insurance did not want to pay for it so it came from a mail away pharmacy for $10. Cannot beat it. Great stuff.

3

Patient Review

7/15/2018

Duexis for Joint Damage causing Pain and Loss of Function

This medication is great for managing pain. I've used it for migraines, back pain, knee pain, and wrist pain with success. It usually kicks in within half an hour, which is awesome. Plus, it doesn't make me drowsy which is a huge plus.

2.7

Patient Review

7/29/2016

Duexis for Joint Damage causing Pain and Loss of Function

2.3

Patient Review

6/15/2017

Duexis for Joint Damage causing Pain and Loss of Function

Durexis helps with the pain from my surgery, but it only lasts for a few hours. I'm glad it exists, but I wish it were more effective.

1

Patient Review

5/21/2016

Duexis for Joint Damage causing Pain and Loss of Function

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about duexis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug DUEXIS used for?

"DUEXIS can be used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis, as well as decrease the risk of developing ulcers of the stomach and upper intestines in people taking ibuprofen for these conditions."

Answered by AI

Is DUEXIS good for inflammation?

"DUEXIS can provide OA and RA symptom relief, including pain and inflammation, when you would prefer to take a medication over having surgery. DUEXIS also has a lower risk of giving you stomach ulcers then ibuprofen taken alone."

Answered by AI

Is DUEXIS stronger than ibuprofen?

"DUEXIS® was also superior to ibuprofen in decreasing the risk for both gastric and duodenal ulcers."

Answered by AI

What is the difference between DUEXIS and ibuprofen?

"Are Duexis and Ibuprofen the Same Thing?

Duexis is a combination of ibuprofen and famotidine, and is used to treat signs and symptoms of rheumatoid arthritis. Because it contains famotidine, Duexis is also effective in reducing the risk of developing upper gastrointestinal ulcers. Ibuprofen is also used to treat primary dysmenorrhea."

Answered by AI

Clinical Trials for Duexis

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Have you considered Duexis clinical trials?

We made a collection of clinical trials featuring Duexis, we think they might fit your search criteria.
Go to Trials
Image of UI Health Care Center for Advanced Reproductive Care in Iowa City, United States.

Ketorolac for Infertility Treatment

18 - 37
Female
Iowa City, IA

Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy. However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle). Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research. This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would. Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia. Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.

Phase 4
Recruiting

UI Health Care Center for Advanced Reproductive Care

Image of University of California, Irvine - UCI Medical Center in Orange, United States.

Sling-Fiber Preservation vs. Conventional POEM for Achalasia

18+
All Sexes
Orange, CA

Peroral endoscopic myotomy (POEM) is an effective, minimally invasive treatment for achalasia, offering excellent rates of symptom relief. However, a significant drawback is the high incidence of gastroesophageal reflux disease (GERD) following the procedure. One proposed technical modification, the selective preservation of the sling fibers during gastric myotomy (SFP-POEM), may reduce this risk without compromising efficacy as compared to a conventional POEM procedure, which includes myotomy of the sling fibers. In this study, adults with achalasia will be randomly assigned to receive one of the two POEM technical approaches. Researchers will monitor whether preserving sling fibers reduces the rates of reflux esophagitis (classified as Los Angeles Grade B or higher) on follow-up endoscopy. Participants will be followed for up to 1 year after the procedure.

Waitlist Available
Has No Placebo

University of California, Irvine - UCI Medical Center

Jason Samarasena, MD, MBA

Have you considered Duexis clinical trials?

We made a collection of clinical trials featuring Duexis, we think they might fit your search criteria.
Go to Trials
Image of Johns Hopkins Hospital in Baltimore, United States.

Fetoscopic Endoluminal Tracheal Occlusion for Congenital Diaphragmatic Hernia

18+
Female
Baltimore, MD

The purpose of this study is to evaluate successful placement and removal of Fetoscopic Endoluminal Tracheal Occlusion (FETO) device in cases of intrathoracic liver herniation with isolated left congenital diaphragmatic hernia (LCDH) with Observed/Expected (O/E) Lung to Head Circumference Ratio (LHR) \< 30% or isolated right congenital diaphragmatic hernia (RCDH) with O/E LHR \< 45%,to compare survival to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation and isolated LCDH with O/E LHR \< 30% that receive FETO procedure performed at 27 weeks 0 days to 29weeks 6 days of gestation to those with intrathoracic liver herniation, isolated LCDH and o/e LRH \< 30% that undergo expectant management, to compare the neonatal survival rate to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation, isolated RCHD with o/e LHR \< 45% that undergo FETO procedure performed at 27 weeks 0 days to 29 weeks 6 days gestation to those with intrathoracic liver herniation, isolated RCHD and o/e LHR \< 45% that elect to proceed with expectant management, to evaluate the frequency of maternal and fetal complications associated with FETO procedure, to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated LCDH survivors with o/e LHR \<30% when compared to isolated LCDH with o/e LRH \<30% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation and to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated RCDH survivors with o/e LHR ≤ 45% when compared to isolated RCHD with LHR \< 45% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation.

Recruiting
Has No Placebo

Johns Hopkins Hospital

Ahmet Baschat, MD

KARL STORZ Endoscopy-America, Inc.

Image of Thomas Jefferson University in Philadelphia, United States.

Physical Therapy for Ventral Hernia

18 - 75
All Sexes
Philadelphia, PA

The goal of this clinical trial is to evaluate the efficacy, safety, and cost-effectiveness of a tailored physical therapy (PT) intervention targeting Abdominal Core Health components in patients recovering from ventral hernia repair. The study focuses on patients aged 18-75 diagnosed with a ventral transverse hernia between 4 cm and 10 cm, scheduled for elective Ventral Hernia Repair (VHR). The main questions it aims to answer are: * Will tailored PT significantly improve abdominal core strength, biomechanical stability, and functional mobility compared to usual care at 3-months post-surgery? * Will tailored PT lead to higher patient-reported quality of life and satisfaction scores, with a lower incidence of post-operative complications such as bowel obstruction and pelvic floor dysfunction over a 1-year follow-up? * Will tailored PT result in decreased healthcare utilization, leading to overall cost savings or neutrality compared to usual care over the first year after VHR? Researchers will compare the tailored physical therapy group to a usual care group to see if the tailored intervention leads to significant improvements in clinical efficacy, patient outcomes, and cost-effectiveness. Participants will: * Be randomly assigned to either the Usual Care Group or the PT Group. * If in the Usual Care Group, receive standard post-operative instructions for 12 weeks, including guidance on binder use, safe lifting, and gradual return to activities. * If in the PT Group, receive foundational post-operative instructions for the first 2 weeks (similar to usual care). Undergo 6 structured and individualized PT sessions over 10 weeks if in the PT Group, with progression based on Oswestry Disability Index (ODI) and Pelvic Floor Distress Inventory-20 (PFDI-20) scores, including Symptom Modulation, Movement Control, Functional Optimization, or Impairment-Based interventions. Participants undergo data collection at 2 weeks, 12 weeks, and 1 year post-operation, including imaging, functional mobility tests, pain scales, patient-reported outcomes, physical measurements, and tracking of complications and healthcare utilization. Participate in semi-structured interviews after the 12-week assessment to provide qualitative insights into their experiences and perceived barriers/facilitators.

Waitlist Available
Has No Placebo

Thomas Jefferson University

Christopher Keating

Have you considered Duexis clinical trials?

We made a collection of clinical trials featuring Duexis, we think they might fit your search criteria.
Go to Trials